Diligence memo · auto-generated · as of July 3, 2026
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Proclara Biosciences, Inc. operates in Biotechnology, based in Cambridge.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Proclara Biosciences, Inc. has raised $77M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $43M on 2016-02-01.
Most recent recorded round closed around 2018-11-09.
Valuation (modeled)modeled
Provath models Proclara Biosciences, Inc. at approximately $284M (range $21M–$747M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.14× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 7.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 6.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.